Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW842166X · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving GW842166 | EXPERIMENTAL | Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive \[carbonyl-\^11C\]GW842166. |
| Name | Type | Description |
|---|---|---|
| GW842166X | DRUG | GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X. |
| [carbonyl-^11C]GW842166 | DRUG | \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution. |
Inclusion Criteria: * Male aged 50 to 80yrs inclusive at the screening visit. * subjects with negative HIV and hepatitis B and C test results within 3 months of study start. Exclusion Criteria: * A negative Allens test on arm to be used for arterial cannulation. * Any contraindications to MRI sca...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Ziltivekimab |
| AstraZeneca PLC | AZN | 1 | - | Undisclosed |
GW842166X is an investigational small molecule being developed for pain and inflammatory conditions. It is a Phase 1 drug candidate that has been studied in a completed clinical trial. The drug is not approved and remains in clinical development.
GW842166X is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for pain and inflammatory indications.
GW842166X is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an imaging study to investigate the distribution of the drug in the brain. The drug is investigational and not yet approved.
GW842166X has one completed clinical trial, NCT00511524, titled "An Imaging Study to Investigate the Distribution of GW842166X in the Brain." This Phase 1 study enrolled 6 healthy male volunteers aged 50 years and older in Sweden.
GW842166X is the drug name used in clinical development. No alternative names have been reported for this investigational compound. It is being studied by GSK plc for pain and inflammatory conditions.